KALA BIO, Inc. (KALA) total debt
KALA BIO, Inc. (KALA) carried total debt of $32.25M at the end of fiscal 2024 (December 31, 2024). That is 11.2% lower than the $36.32M of fiscal 2023. Figures as of 18 Nov 2026, 12:35 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2024
- $32.25M
- Change on fiscal 2023
- −11.2%
- Growth, 5 years
- −15.5% a year
- Highest on record
- $80.00Mfiscal 2021
- Lowest on record
- $9.65Mfiscal 2016
- Fiscal years on record
- 92016–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
KALA BIO, Inc. total debt, in more detail
Over the five fiscal years to 2024 total debt shrank at a compound 15.5% a year. Across the 9 fiscal years on record (2016–2024), the highest was $80.00M in fiscal 2021 and the lowest $9.65M in fiscal 2016.
Total debt was 2.6× shareholders' equity at the end of fiscal 2024.
Total debt by fiscal year
KALA BIO, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2024 | $32.25M | 11.2% down | 2.6× | |
| 2023 | $36.32M | 15.4% down | 4.8× | |
| 2022 | $42.95M | 46.3% down | 2.3× | |
| 2021 | $80.00M | 6.7% up | 4.8× | |
| 2020 | $75.00M | 0.0% | 0.8× | |
| 2019 | $75.00M | 0.0% | 2.5× | |
| 2018 | $75.00M | 297.1% up | 0.7× | |
| 2017 | $18.89M | 95.7% up | 0.2× | |
| 2016 | $9.65M | — | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
KALA BIO, Inc., figure by figure
- KALA BIO, Inc. market cap
- KALA BIO, Inc. revenue
- KALA BIO, Inc. earnings
- KALA BIO, Inc. earnings per share (EPS)
- KALA BIO, Inc. P/E ratio
- KALA BIO, Inc. P/S ratio
- KALA BIO, Inc. P/B ratio
- KALA BIO, Inc. free cash flow
- KALA BIO, Inc. operating margin
- KALA BIO, Inc. dividend
- KALA BIO, Inc. shares outstanding
- KALA BIO, Inc. cash on hand
- KALA BIO, Inc. total assets
- KALA BIO, Inc. return on equity (ROE)
- KALA BIO, Inc. return on invested capital (ROIC)
KALA BIO, Inc. (KALA) overview: price, valuation and scorecard
KALA BIO, Inc. total debt: questions and answers
How much debt does KALA BIO, Inc. have?
KALA BIO, Inc. (KALA) carried total debt of $32.25M at the end of fiscal 2024 (December 31, 2024). That is 11.2% lower than the $36.32M of fiscal 2023.
What is the growth rate of KALA BIO, Inc.'s total debt?
Over the five fiscal years to 2024 total debt shrank at a compound 15.5% a year.
What are the highest and lowest total debt figures on record for KALA BIO, Inc.?
Across the 9 fiscal years on record (2016–2024), the highest was $80.00M in fiscal 2021 and the lowest $9.65M in fiscal 2016.
How does KALA BIO, Inc.'s debt compare with its equity?
Total debt was 2.6× shareholders' equity at the end of fiscal 2024.
How is KALA BIO, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For KALA BIO, Inc. it is on record here for 9 fiscal years, 2016 to 2024.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “KALA BIO, Inc. (KALA) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/KALA/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.